Abstract
Conventional serotonin-enhancing antidepressants including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) have shown effectiveness in the treatment of major depression, but their significant limitations such as slowness of action have led to intensive research efforts to develop new antidepressants. Increased synaptic neurotransmission of serotonin (5-hdroxytryptamine; 5-HT) through orchestration of stimulation and blockade of various subtypes of 5-HT receptors is involved in the mechanisms of action of SSRIs. Agonists at the 5-HT1A, 5-HT1B, 5-HT2C, 5-HT4, and 5-HT6 receptors and antagonists at the 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5- HT6, and 5-HT7 receptors have shown antidepressant properties in clinical and preclinical studies. However, paradoxical antidepressant-like effects of both agonists and antagonists at particular 5-HT receptors suggest the need to consider the neurochemical mechanisms of each 5-HT receptor subtype. Therefore, better knowledge of the involvement of individual 5-HT receptors in the mechanisms of action of currently used antidepressants as well as antidepressant effects of selective ligands of 5- HT receptor subtypes will provide opportunities for the development of future antidepressants with more rapid onset of action, fewer side effects, and better efficacy than SSRIs.
Keywords: Serotonin, antidepressant, depression, SSRI, synaptic neurotransmission of serotonin, selective serotonin reuptake inhibitors.
Current Pharmaceutical Design
Title:Recent Developments on Future Antidepressant-related Serotonin Receptors
Volume: 24 Issue: 22
Author(s): Meysam Amidfar and Yong-Ku Kim*
Affiliation:
- Department of Psychiatry, College of Medicine, Korea University, Seoul,South Korea
Keywords: Serotonin, antidepressant, depression, SSRI, synaptic neurotransmission of serotonin, selective serotonin reuptake inhibitors.
Abstract: Conventional serotonin-enhancing antidepressants including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) have shown effectiveness in the treatment of major depression, but their significant limitations such as slowness of action have led to intensive research efforts to develop new antidepressants. Increased synaptic neurotransmission of serotonin (5-hdroxytryptamine; 5-HT) through orchestration of stimulation and blockade of various subtypes of 5-HT receptors is involved in the mechanisms of action of SSRIs. Agonists at the 5-HT1A, 5-HT1B, 5-HT2C, 5-HT4, and 5-HT6 receptors and antagonists at the 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, 5- HT6, and 5-HT7 receptors have shown antidepressant properties in clinical and preclinical studies. However, paradoxical antidepressant-like effects of both agonists and antagonists at particular 5-HT receptors suggest the need to consider the neurochemical mechanisms of each 5-HT receptor subtype. Therefore, better knowledge of the involvement of individual 5-HT receptors in the mechanisms of action of currently used antidepressants as well as antidepressant effects of selective ligands of 5- HT receptor subtypes will provide opportunities for the development of future antidepressants with more rapid onset of action, fewer side effects, and better efficacy than SSRIs.
Export Options
About this article
Cite this article as:
Amidfar Meysam and Kim Yong-Ku *, Recent Developments on Future Antidepressant-related Serotonin Receptors, Current Pharmaceutical Design 2018; 24 (22) . https://dx.doi.org/10.2174/1381612824666180803111240
DOI https://dx.doi.org/10.2174/1381612824666180803111240 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Influence of the Novelty-Seeking Endophenotype on the Rewarding Effects of Psychostimulant Drugs in Animal Models
Current Neuropharmacology The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease
Current Alzheimer Research CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of the MAGUK Protein CASK in Neural Development and Synaptic Function
Current Medicinal Chemistry Cholinotrophic Molecular Substrates of Mild Cognitive Impairment in the Elderly
Current Alzheimer Research Sustained Release In Situ Implant of Arteether Based on Transition of Smedds into Lyotropic Liquid Crystalline Phases
Current Nanomedicine Neurotoxic and Neuroprotective Role of Exosomes in Parkinson’s Disease
Current Pharmaceutical Design MicroRNA Therapeutics in Neurological Disease
Current Pharmaceutical Design The Click Test: A Novel Tool to Quantify the Age-Related Decline of Fast Motor Sequencing of the Thumb
Current Aging Science Effects of Paliroden (SR57667B) and Xaliproden on Adult Brain Neurogenesis
Current Alzheimer Research Prepare and Assessment of a New Purity Certified Reference Material of Quercetin
Current Analytical Chemistry The Current Use of Mass Spectrometry in Combination with Other Separation Techniques in Drug Discovery Arena
Medicinal Chemistry Hypersensitivity to Lamotrigine and Nonaromatic Anticonvulsant Drugs: A Review
Current Pharmaceutical Design Statin Related Memory Dysfunction in a Nigerian Woman: A Case Report
Current Drug Safety Microarray Data Integration: Frameworks and a List of Underlying Issues
Current Bioinformatics Therapies in Development for Non-Infectious Uveitis
Current Molecular Medicine Experimental Models for Aging and their Potential for Novel Drug Discovery
Current Neuropharmacology 2, 7-Diarylidene-cycloheptanone, Hydrazonoyl Chlorides and Heterocyclic Amines as Precursors for Synthesis of Bioactive new Fused Cycloheptapyrimidine Derivatives
Current Organic Synthesis ApoE ε4 Allele Related Alterations in Hippocampal Connectivity in Early Alzheimer’s Disease Support Memory Performance
Current Alzheimer Research Understanding the Structural Basis for Inhibition of Cyclin-Dependent Kinases. New Pieces in the Molecular Puzzle
Current Drug Targets